Efficacy and Safety of Shea Nut Oil in Hemophilic Arthropathy

Hemophilia Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02569359
• Other study ID #: 1-104-05-041
• Status: Terminated
• Phase: N/A
• Start date: April 2016
• Est. completion date: September 2018

Study information

• Verified date: April 2021
• Source: Tri-Service General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Recurrent hemarthrosis results in synovitis and destructive arthropathy in hemophilic patients. Prophylactic replacement, physical therapy, cyclooxygenase-2 (COX-2) inhibitors, corticosteroids, and radionucleotide synovectomy are some of the typical modalities used in the managements hemophilic synovitis and arthropathy. In clinical practice, the choice of non-steroidal anti-inflammatory drugs (NSAIDs) also needs to take into consideration the risk for cardiovascular events and should be used at the lowest effective dose and for the shortest duration.This study will investigate the safety and efficacy of Shea nut oil for the treatment of hemophilic arthropathy.

Description:

Hemophilia is an X-linked recessive bleeding disorder caused by a deficiency of coagulation factor VIII (hemophilia A) or IX (hemophilia B). Severe hemophilia patients may have frequent spontaneous bleeding episodes such as joint and muscle bleeding. Repeated joint bleeding leads to chronic synovitis, cartilage damage and bony destruction, which is associated with range of motion (ROM) limitation, pain, muscle atrophy, functional impairment and poor quality of life. Around 80% of all spontaneous joint bleeds occur in the ankles, knees and elbows. Hemophilic arthropathy is a multifactorial event and there is evidence to suggest that iron may play a major role with release of cytokines such as Interleukin-1, Interleukin-6, and tumor necrosis factor-α (TNF-α) eading to chronic proliferative synovitis, hypervascularity, and progressive arthropathy . Prophylactic replacement , physical therapy, COX-2 inhibitors , corticosteroids, and radionucleotide synovectomy are some of the typical modalities used in the managements hemophilic synovitis and arthropathy. The onset of joint bleedings in severe hemophilia occurs approximately 23 months of age and arthropathy could be marked in adolescents or young adults. Some hemophilia patients may either not be good candidates for surgery or may prefer not to have surgery. The traditional Africans have used African Shea tree and shea nuts oil extracts to treat arthritis. Shea nut oil contains are a mixture of fatty acid and cinnamic acid esters of such triterpene alcohols as α-amyrine, β-amyrine, butyrospermol, lupeol and to aminor extent, sterols, aliphatic alcohols, and karitene. Triterpene alcohols such as lupeol and α/β-amyrine have been shown to possess anti-inflammatory effects, especially in their esterified forms. In 1998, US Food and Drug Administration approved shea nut oil as a safe food additive. The shea nut oil used in this trial is a patented concentrate containing approximately 50% triterpenes derived from the seed of the shea tree, Vitellaria paradoxa. The most abundant triterpenes in shea nut oil areα-amyrin(54.6%), β-amyrin(12.3%), Lupeol(17%) plus their dihydro-derivatives. Cheras et al. reported that shea nut oil extract treatment over the 15 weeks of their random double-blind study in upper quartile of 89 osteoarthritis patients was effective in decreasing inflammation marker TNF-α (23.9% vs 6%, treatment vs placebo) and cartilage degradation marker C-terminal crosslinked telopeptide type II collagen (CTX-II) (28.7% vs an increase of 17.6%, treatment vs placebo). Chen and his colleagues carried out a 16-week study in 33 patients with osteoarthritis of knee joint and found shea nut oil was effective in increasing activity and thickness of vastus medialis, and decreasing pain and stiffness of knee joint. Late stage of hemophilic arthropathy is characterized by advanced cartilage degeneration and joint destruction. These effects on cartilage and subchondral bone are degenerative and inflammatory in nature, similar to the changes in osteoarthritis. Management of chronic hemophilic arthropathy is difficult. NSAIDs have been used with caution in patients with bleeding disorders because of their inhibition of platelet function and gastrointestinal side effects. In clinical practice, the choice of NSAIDs also needs to take into consideration the risk for cardiovascular events and should be used at the lowest effective dose and for the shortest duration. This study will investigate the safety and efficacy of Shea nut oil for the treatment of hemophilic arthropathy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: September 2018
• Est. primary completion date: September 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

• age 20 years and above
• hemophilia A or B patients who reported painful (VAS = 3) hemophilic arthropathy in ankles, elbows or knees for at least 6 months.

Exclusion Criteria:

• presence of joint infections
• any surgery on the joint in preceding 6 months
• intra-articular HA injection within the past 6 months
• history of rheumatoid arthritis,
• gouty arthropathy
• presence of neoplasm,
• allergy to shea nut oil production
• use of corticosteroids within 3 weeks prior to baseline and throughout the study
• use of anti-inflammatory agents 3 weeks prior to baseline and for the duration of the study,
• history of trauma associated with the signal joint,
• liver function tests greater than twice the upper limit of normal at baseline
• history of alcohol or substance abuse.

Related Conditions & MeSH terms

• Hemophilia
• Hemophilic Arthropathy
• Joint Diseases

Intervention

Dietary Supplement:
• shea nut oil extract

Other:
• Placebo

Locations

Country	Name	City	State
Taiwan	Hemophilia care and research center	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Tri-Service General Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain (visual analogue scale) and Change from Baseline Pain at 1 &3 months	The pain intensity will be evaluated subjectively on a visual analogue scale (0-100mm).	baseline, 1 month, 3 months
Secondary	CTX-II (ng/mmol creatinine) and Change from Baseline at 1 & 3 months	C-telopeptide fragments of type II collagen (CTX-II) in urine is a measure of type II collagen degradation and a biological marker of arthropathy.	baseline, 1 month, 3 months
Secondary	Tumor Necrosis Factor alpha (pg/mL) and Change from Baseline at 1 & 3 months	TNF-alpha are one of inflammatory mediators that increase following hemarthrosis in hemophilic mice. Plasma samples will tested by ELISA.	baseline, 1 month, 3 months
Secondary	Ultrasonographic synovial thickness (mm) and Change from Baseline at 1 &3 months	Synovial thickness (mm) by ultrasonography were evaluated from the lateral, middle, and medial aspects of the anterior suprapatellar recess	baseline, 1 month, 3 months
Secondary	Synovial hyperemia (score) and Change from Baseline at 1& 3 months	Power Doppler assessment of selected synovial sites is carried out with settings standardized to a pulse repetition frequency of 700 Hz. The intensity of the blood flow in the synovium is scored into 0 to 3 (0=No flag; 1 = 1 flag; 2 = 2-3 flags; 3=>3 flags) adapted from Klukowska and Melchiorre et al	baseline, 1 month, 3 months
Secondary	Short Form -36 score and Change from Baseline at 1 & 3 months	The SF-36 is filled out taking into account the person's condition in the last one month and scores range from 0 to 100, with higher scores indicating better health-related quality of life.	baseline, 1 month, 3 months
Secondary	Hemophilia Joint Health Score (HJHS) and Change from Baseline at 1 & 3 months	The HJHS is a structured physical examination score evaluating the joint health in hemophilia patient. The score for each joint is the sum of the individual items including swelling, swelling duration, muscle atrophy, axial alignment, crepitus of motion, flexion loss & extension loss, joint pain and strength. A score of 20 suggests the worst possible damage/impairment in the evaluating joint.	baseline, 1 month, 3 months